

August 21, 2023

Department of Corporate Services **BSE Limited**Phiroze Jeejeebhoy Towers
Dalal Street, Fort **Mumbai - 400 001.** 

Dear Sir,

Sub: Submission of IDC Recommendation in respect of the proposed Open Offer to the shareholders of Unichem Laboratories Limited (target Company) under Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 [SEBI SAST Regulations] by the Acquirer

In terms of Regulation 26(7) of the SEBI SAST Regulations, the Committee of Independent Directors (IDC) of the Target Company have given their recommendation on the open offer and the same has been published today in the following publications where the Detailed Public Statement was made:

- 1. Business Standard, English, all editions
- 2. Business Standard, Hindi, all editions
- 3. Mumbai Lakebundeen (Regional Marathi dailu Mumbai).

In compliance of Regulation 26(7)(ii) of the SEBI SAST Regulations, we have enclosed the relevant cutting of the newspaper wherein the recommendation of the IDC has appeared, to enable you to disseminate the same to public.

Thanking you,

Yours faithfully,

For Arihant Capital Markets Limited

Sundar Rangan

Head - Merchant Banking

Encl: as above



Registered Office: Unichem Bhavan, Prabhat Estate, Off S.V. Road, Jogeshwari West, Mumbai - 400102

CIN: L99999MH1962PLC012451; Tel: 022-66888333; E-mail: shares@unichemlabs.com; Website: www.unichemlabs.com Recommendation of Committee of Independent Directors (IDC) on the Open Offer to the Equity Shareholders of Unichem Laboratories Limited

(Target Company/TC) by Ipca Laboratories Limited ("the Acquirer") for acquisition of upto 1,83,05,495 Equity Shares under Regulations 3(1)

and 4 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("SEBI SAST Regulations"). 1. Date August 9, 2023 2. Name of Target Company Unichem Laboratories Limited 3 Detail of the Offer pertaining to TC Open Offer is being made by Ipca Laboratories Limited ("the Acquirer") to equity Shareholders of the TC for acquiring upto 1,83,05,495 Equity Shares of the face value of ₹ 2/- each of the TC at a price of ₹ 440/- (Rupees Four Hundred Forty only) per equity share payable in cash in terms of Regulation 3(1) and 4 of SEBI SAST Regulations. Acquirer is Ipca Laboratories Limited 4 Name of the Acquirer and PAC with the Acquirer 5. Name of the Manager to the Open Offer Arihant Capital Markets Limited, SEBI Regn No. INM000011070 Mr. Prafull Anubhai Chairman 6. Members of the Independent Director Committee (IDC) Mr. Prafull Sheth Member Mr. Anand Mahajan Member Ms. Priti Puri Member Mr. Prafull Anubhai, Mr. Prafull Sheth, Mr. Anand Mahajan and Ms. Priti Puri are 7 IDC member's relationship with the TC (Director, Equity Owned, any other Directors of the TC. Except for this, they do not have any relationship with the contract /relationship), if any Trading in the Equity shares /other 8 Save for the following, none of the IDC members have traded in the Equity Shares/ other securities of the TC after the date of Public Announcement by the Acquirer: Securities of the TC by IDC members (a) Sale of 682 Equity Shares (constituting 0.001% of the paid-up capital of the TC) in the month of May 2023 by Mr. Prafull Anubhai. Sale of 15,029 Equity Shares (constituting 0.02% of the paid-up capital of the TC) during the period from May 2023 to July 2023 by Mr. Anand Mahajan. IDC Member's relationship with the Acquirer None of the IDC Members have any relationship with the Acquirer in any way. (Director, Equity shares owned, any other contract /relationship), if any Trading in Equity shares/other securities 10. IDC members have not traded with any securities of the Acquirer. of the Acquirer by IDC members 11. Recommendation to the Open offer, as to IDC is of the considered view that the Open Offer Price of ₹ 440/- per Equity Share whether the offer is fair and reasonable is fair and reasonable. 12. IDC have reviewed the Public Announcement dated April 24, 2023, Detailed Public Summary of reasons for recommendation

Any other matter to be highlighted To the best of our knowledge and belief, and after making proper enquiry, and considering the information contained in and/or accompanying this statement in all material respects, is true and correct and not misleading, whether by omission of any information or otherwise, and includes all the information required to be disclosed by Target Company under the SEBI SAST Regulations.

SAST Regulations.

For Unichem Laboratories Limited

Statement and the Draft Letter of Offer filed with SEBI and looked at the Negotiated Price and Volume Weighted Average Price of the Target Company for a period of 60 trading days immediately preceding the date of the Public Announcement and was convinced that the offer price ₹ 440/- (Rupees Four Hundred Forty only) per Equity Share is highest of both the values and is computed in accordance with the SEBI

Based on the above, the IDC is of opinion that offer price to the shareholders of the Target Company is fair and reasonable. However shareholders are advised to

independently evaluate the Offer and take an informed decision.

Place: Mumbai Date: August 9, 2023

Details of Independent Advisors, if any

13.

Prafull Anubhai Chairman-IDC

NII

NII

Prafull Sheth Member-IDC Anand Mahajan Member-IDC

Priti Puri Member-IDC